Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 9 | 2021 | 220 | 1.080 |
Why?
|
| Islets of Langerhans Transplantation | 5 | 2012 | 179 | 0.410 |
Why?
|
| Islets of Langerhans | 3 | 2012 | 286 | 0.380 |
Why?
|
| Pancreatic Ducts | 2 | 2008 | 31 | 0.330 |
Why?
|
| Tissue Donors | 3 | 2023 | 146 | 0.320 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2021 | 114 | 0.290 |
Why?
|
| Donor Selection | 2 | 2018 | 15 | 0.290 |
Why?
|
| Kidney Neoplasms | 2 | 2021 | 174 | 0.280 |
Why?
|
| Interleukin-8 | 1 | 2008 | 95 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 234 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2012 | 630 | 0.240 |
Why?
|
| Frailty | 2 | 2018 | 130 | 0.230 |
Why?
|
| Lithotripsy, Laser | 1 | 2023 | 5 | 0.200 |
Why?
|
| Kidney Calculi | 1 | 2023 | 34 | 0.190 |
Why?
|
| Hepatitis A | 1 | 2020 | 7 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 25 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 103 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 324 | 0.150 |
Why?
|
| Liver | 3 | 2018 | 869 | 0.150 |
Why?
|
| Telepathology | 1 | 2018 | 5 | 0.150 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 12 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 18 | 0.140 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 13 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2018 | 38 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 35 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 46 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2003 | 490 | 0.140 |
Why?
|
| Sarcopenia | 1 | 2018 | 28 | 0.140 |
Why?
|
| Hepatitis | 1 | 2018 | 58 | 0.140 |
Why?
|
| Smartphone | 1 | 2018 | 73 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 196 | 0.130 |
Why?
|
| Mobile Applications | 1 | 2018 | 140 | 0.120 |
Why?
|
| Treatment Outcome | 8 | 2023 | 5784 | 0.120 |
Why?
|
| Health Care Rationing | 1 | 2016 | 21 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2016 | 56 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2017 | 145 | 0.120 |
Why?
|
| Kidney | 1 | 2017 | 450 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 191 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 380 | 0.100 |
Why?
|
| Humans | 18 | 2023 | 65100 | 0.100 |
Why?
|
| Male | 12 | 2021 | 31017 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 309 | 0.090 |
Why?
|
| Graft Survival | 3 | 2018 | 296 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 286 | 0.090 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 88 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1559 | 0.080 |
Why?
|
| Middle Aged | 8 | 2021 | 18254 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 542 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 71 | 0.080 |
Why?
|
| Chorioallantoic Membrane | 1 | 2008 | 2 | 0.070 |
Why?
|
| Chick Embryo | 1 | 2008 | 46 | 0.070 |
Why?
|
| C-Peptide | 2 | 2009 | 24 | 0.070 |
Why?
|
| Rats, Wistar | 1 | 2008 | 182 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2008 | 80 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 195 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 113 | 0.070 |
Why?
|
| Adult | 7 | 2019 | 17351 | 0.060 |
Why?
|
| Pancreas Transplantation | 1 | 2006 | 19 | 0.060 |
Why?
|
| Mice, Inbred NOD | 1 | 2008 | 526 | 0.060 |
Why?
|
| Tacrolimus | 2 | 2021 | 63 | 0.060 |
Why?
|
| Female | 9 | 2019 | 34000 | 0.060 |
Why?
|
| Mycophenolic Acid | 2 | 2021 | 68 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2008 | 2188 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 710 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1113 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2018 | 6860 | 0.060 |
Why?
|
| Gene Expression | 1 | 2008 | 852 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 1006 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 1989 | 0.050 |
Why?
|
| Thromboplastin | 1 | 2004 | 6 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 497 | 0.050 |
Why?
|
| Cytokines | 1 | 2008 | 952 | 0.050 |
Why?
|
| Portal System | 1 | 2003 | 3 | 0.050 |
Why?
|
| Ureteroscopy | 1 | 2023 | 19 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 456 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 75 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 240 | 0.050 |
Why?
|
| Insulin | 3 | 2012 | 695 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2021 | 58 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 33 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 37 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 110 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 388 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 47 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 125 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 206 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 14946 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 663 | 0.040 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 5 | 0.040 |
Why?
|
| Adolescent | 3 | 2016 | 6305 | 0.040 |
Why?
|
| Mice | 2 | 2012 | 11097 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2018 | 373 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 5423 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 420 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 67 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 402 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 94 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 52 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 5607 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4810 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1779 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 216 | 0.030 |
Why?
|
| United States | 2 | 2019 | 8093 | 0.030 |
Why?
|
| Animals | 2 | 2012 | 21308 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1698 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1270 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 882 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1477 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 2144 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2619 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 206 | 0.020 |
Why?
|
| Immune System | 1 | 2012 | 132 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 3762 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 587 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 22 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 327 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 301 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 463 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 173 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1187 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3470 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2009 | 525 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2004 | 6 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 844 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 662 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 896 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 2483 | 0.010 |
Why?
|